TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3984771

Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl withdrawal
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 29343509

Group type: EXPERIMENTAL
Intervention: Tregalizumab 25 mg
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Tregalizumab 100 mg
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Tregalizumab 200 mg
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 26811968

Group type: EXPERIMENTAL
Intervention: CHoBI7 intervention (hand washing with soap and water treatment)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 439
Study: 24980662

Group type: EXPERIMENTAL
Intervention: Vitamin D3 200,000 IU for 2 months followed by 100,000 IU monthly for 18 months
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 21956241

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 20179653

Group type: EXPERIMENTAL
Intervention: Airway Scope (AWS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Macintosh laryngoscope (MLS)
Number of subjects: 36
Study: 17636181

Group type: EXPERIMENTAL
Intervention: Spa treatment course in Tunisia
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Spa treatment
Number of subjects: 134

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 134
Study: 16042774

Group type: EXPERIMENTAL
Intervention: Bronchoalveolar lavage fluid analysis for SP‐B, SP‐C and their proforms
Number of subjects: 62
Study: 12443741

Group type: EXPERIMENTAL
Intervention: Lignocaine (5 ml of 1% lignocaine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline placebo (5 ml)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Carotid sinus nerve excision
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Lignocaine
Number of subjects: 80
Study: 10502216

Group type: EXPERIMENTAL
Intervention: Efegatran sulfate plus streptokinase (1.5 million U)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Heparin plus accelerated tissue plasminogen activator (TPA)
Number of subjects: 245
Study: 8952600

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 82
Study: 1743190

Group type: EXPERIMENTAL
Intervention: ioversol (Optiray)
Number of subjects: 743

Group type: COMPARATOR
Intervention: monomeric nonionic reference product
Number of subjects: 743
Study: 7206052

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (600 mg per M², administered intravenously weekly)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin and 5-fluorouracil
Number of subjects: 118
Study: 30853622

Group type: EXPERIMENTAL
Intervention: Carob supplementation (SG, n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (PG, n = 12)
Number of subjects: 23
Study: 29174928

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 0.5 g IN
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 1.0 g IN
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: 2.0 g IN
Number of subjects: 86
Study: 26887289

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22815250

Group type: EXPERIMENTAL
Intervention: First-generation FlatStent device
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Second-generation FlatStent EF device
Number of subjects: 95

Group type: COMPARATOR
Intervention: Both devices
Number of subjects: 95
Study: 21557777

Group type: EXPERIMENTAL
Intervention: Intralesional cryosurgery with pain-control protocol (oral pain-relief tablets Dipyrone and translesional local anaesthesia with Bupivacaine hydrochloride 0.5%)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Contact cryosurgery with pain-control protocol
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (contact cryosurgery without pain-control protocol)
Number of subjects: 29
Study: 21180792

Group type: EXPERIMENTAL
Intervention: Toothbrushing with sonic toothbrush after exposure to acid substances
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Toothbrushing with sonic toothbrush plus dentifrice after exposure to acid substances
Number of subjects: 25

Group type: COMPARATOR
Intervention: Exposure to different acid substances (orange, cola drink, vinegar, white wine, lemon juice)
Number of subjects: 25
Study: 17688080

Group type: EXPERIMENTAL
Intervention: Monodoks 100 mg capsule (test preparation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 100 mg capsule of the originator product (reference preparation)
Number of subjects: 24
Study: 16378560

Group type: EXPERIMENTAL
Intervention: Telephone triage for routine asthma care
Number of subjects: 194

Group type: COMPARATOR
Intervention: Usual clinic care
Number of subjects: 194
Study: 12443524

Group type: EXPERIMENTAL
Intervention: Combined physiotherapy program (manual therapy, exercise, education)
Number of subjects: 57
Study: 10501820

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 6.25 microg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 12.5 microg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 25 microg
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oxymetazoline 50 microg
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 7852490

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy (0.04 +/- 0.01 IU/kg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 40
Study: 2045853

Group type: EXPERIMENTAL
Intervention: MAb DF3
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: MAb CU18
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: MAb F36/22
Number of subjects: 190

Group type: COMPARATOR
Intervention: Control (no specific antibody mentioned)
Number of subjects: 190
Study: 6988941

Group type: EXPERIMENTAL
Intervention: Liquid antacid preparation (Link)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30939085

Group type: EXPERIMENTAL
Intervention: Hypnotic intervention
Number of subjects: 25

Group type: COMPARATOR
Intervention: Minimal-effect treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 25
Study: 27841098

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 26093776

Group type: EXPERIMENTAL
Intervention: Financial incentives plus text message reminders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Text message reminders alone
Number of subjects: 0
Study: 24029304

Group type: EXPERIMENTAL
Intervention: DBT guided self-help (DBTgsh); 6 support calls over 13 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DBT guided self-help (DBTgsh); assessed at 6-month follow-up
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wait-list (WL) control group
Number of subjects: 60
Study: 21544313

Group type: EXPERIMENTAL
Intervention: edoxaban 30 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: edoxaban 60 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: edoxaban 120 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: fondaparinux 2.5 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study: 19246254

Group type: EXPERIMENTAL
Intervention: Itopride determination method using high-performance liquid chromatography with fluorimetric detection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bioequivalence study samples
Number of subjects: 0
Study: 17956811

Group type: EXPERIMENTAL
Intervention: Auditory discrimination therapy (ADT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 10607319

Group type: EXPERIMENTAL
Intervention: Skin photoaging assessment using the Larnier skin photoaging photographic scale.
Number of subjects: 9363

Group type: EXPERIMENTAL
Intervention: Age as a variable related to skin photoaging in women.
Number of subjects: 9363

Group type: EXPERIMENTAL
Intervention: Phototype as a variable related to skin photoaging in women.
Number of subjects: 9363

Group type: EXPERIMENTAL
Intervention: Menopausal status as a variable related to skin photoaging in women.
Number of subjects: 9363

Group type: EXPERIMENTAL
Intervention: Geographic location as a variable related to skin photoaging in women.
Number of subjects: 9363

Group type: EXPERIMENTAL
Intervention: Age as a variable related to skin photoaging in men.
Number of subjects: 9363

Group type: EXPERIMENTAL
Intervention: Geographic location as a variable related to skin photoaging in men.
Number of subjects: 9363

Group type: EXPERIMENTAL
Intervention: Phototype as a variable related to skin photoaging in men.
Number of subjects: 9363
Study: 9162303

Group type: EXPERIMENTAL
Intervention: DFMO 0.125 g/day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: DFMO 0.25 g/day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: DFMO 0.5 g/day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: DFMO 1.0 g/day
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: DFMO doses of > or = 1 g/day
Number of subjects: 76
Study: 1995527

Group type: EXPERIMENTAL
Intervention: 4 x 8.0 Gy
Number of subjects: 137

Group type: COMPARATOR
Intervention: 20 x 2.5 Gy
Number of subjects: 137
Study: 6390823

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 299

Group type: COMPARATOR
Intervention: Nonsplenectomy
Number of subjects: 299
Study: 30826791

Group type: EXPERIMENTAL
Intervention: Placental growth factor testing (unblinded point of care test)
Number of subjects: 4000
Study: 30320677

Group type: EXPERIMENTAL
Intervention: 1-hour group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 2-hour group
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 3-hour group
Number of subjects: 3
Study: 25864771

Group type: EXPERIMENTAL
Intervention: Intraoral scanning (IOS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Classical polyether impressions
Number of subjects: 20
Study: 24843313

Group type: EXPERIMENTAL
Intervention: Oxycodone (1 mg) and ketorolac (1.5 mg)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Fentanyl (10 mcg) and ketorolac (1.5 mg)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 81

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Oxycodone and Fentanyl
Number of subjects: 81
Study: 23122650

Group type: EXPERIMENTAL
Intervention: Alemtuzumab 12 mg
Number of subjects: 667

Group type: COMPARATOR
Intervention: Interferon beta 1a
Number of subjects: 667
Study: 20730665

Group type: EXPERIMENTAL
Intervention: Immediate online support condition
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waitlisted control condition
Number of subjects: 30
Study: 16533870

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg before CS/US pairing
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Flumazenil 1 mg before conditioning
Number of subjects: 42

Group type: COMPARATOR
Intervention: Flumazenil 1 mg after conditioning
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo/saline/saline
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Diazepam/saline/saline
Number of subjects: 42
Study: 15448917

Group type: EXPERIMENTAL
Intervention: Borderline Personality Disorder (BPD) group
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: BPD group
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Therapy for BPD
Number of subjects: 478
Study: 11876690

Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha-2b (10 MU daily for 10 days, then 5 MU daily for 74 days, then 5 MU three times weekly for 24 weeks)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha-2b with ribavirin (1000-1200 mg/day starting at day 11)
Number of subjects: 25

Group type: COMPARATOR
Intervention: High-dose interferon alpha-2b
Number of subjects: 25
Study: 10215775

Group type: EXPERIMENTAL
Intervention: Intermittent therapy (200 mg twice daily for 1 week per month for 3 months)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Continuous therapy (200 mg once daily for 3 months)
Number of subjects: 129
Study: 7759273

Group type: EXPERIMENTAL
Intervention: music therapy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: music-video therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: scheduled rest group
Number of subjects: 96
Study: 2186658

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with fentanyl 100 mcg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% plain
Number of subjects: 60
Study: 31940279

Group type: EXPERIMENTAL
Intervention: Acromegaly group
Number of subjects: 178

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 178
Study: 30681719

Group type: EXPERIMENTAL
Intervention: Cervical length (CL) ≤11 mm
Number of subjects: 119

Group type: COMPARATOR
Intervention: Cervical length (CL) >11 mm
Number of subjects: 119
Study: 29310376

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 μg and morphine 100 μg (FM group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Morphine 100 μg (M group)
Number of subjects: 60
Study: 24986038

Group type: EXPERIMENTAL
Intervention: Qsymia (phentermine 7.5 mg plus topiramate 46.0 mg)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Diet and lifestyle advice plus placebo
Number of subjects: 93
Study: 23159018

Group type: EXPERIMENTAL
Intervention: R-REM training intervention for nursing staff
Number of subjects: 1405
Study: 22087680

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (2 g per day)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Azathioprine (2 mg per kilogram of body weight per day)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 227

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 227
Study: 20002061

Group type: COMPARATOR
Intervention: 50 g activated charcoal (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 25 g activated charcoal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 g activated charcoal
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 50 g activated charcoal
Number of subjects: 16
Study: 17635578

Group type: EXPERIMENTAL
Intervention: Inhaled PACAP38 (cumulative dose of 480 microg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled PACAP38
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study: 15240645

Group type: EXPERIMENTAL
Intervention: Abacavir (replacement of protease inhibitor)
Number of subjects: 8
Study: 11777752

Group type: EXPERIMENTAL
Intervention: Intact tablet after high-fat breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablet split into three fragments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fractional dosing (40 mg in the morning and 20 mg in the evening)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once daily dosing
Number of subjects: 0
Study: 9694707

Group type: EXPERIMENTAL
Intervention: 2 mg cyanocobalamin orally daily for 120 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: 1 mg cyanocobalamin intramuscularly on days 1, 3, 7, 10, 14, 21, 30, 60, and 90
Number of subjects: 38
Study: 8087823

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (ISMN) 20 mg b.i.d.
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (ISMN) 5 mg b.i.d.
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate (ISMN) 10 mg b.i.d.
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study: 2490902

Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flurazepam
Number of subjects: 0
Study: 848618

Group type: EXPERIMENTAL
Intervention: Home visits by community members trained to take blood pressure measurements (BPMs)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Passive techniques such as invitational letters and gift offers
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Prior informational letters specifying time of visit
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (fifth target area)
Number of subjects: 800
Study: 31002769

Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no PtDA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Intervention group (with PtDA)
Number of subjects: 35
Study: 28138158

Group type: EXPERIMENTAL
Intervention: Intravenous administration of low-dose endotoxin (0.8 ng/kg body weight)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Endotoxin treatment
Number of subjects: 18
Study: 25249577

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 28
Study: 22112682

Group type: EXPERIMENTAL
Intervention: Nifedipine CR
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Efonidipine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 50
Study: 21761252

Group type: EXPERIMENTAL
Intervention: Anterolateral skin incision
Number of subjects: 69

Group type: COMPARATOR
Intervention: Midline skin incision
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Entire group
Number of subjects: 69
Study: 19242484

Group type: EXPERIMENTAL
Intervention: Postural support (nesting with rolled-up towels)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Care model used by the unit (no postural support)
Number of subjects: 47
Study: 16479409

Group type: EXPERIMENTAL
Intervention: Diprivan 1%
Number of subjects: 10

Group type: COMPARATOR
Intervention: Propofol 1% MCT Fresenius
Number of subjects: 10
Study: 12548315

Group type: EXPERIMENTAL
Intervention: Single dose of virgin olive oil (50 ml)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sustained doses of virgin olive oil (25 ml/day for one week)
Number of subjects: 7
Study: 10928528

Group type: EXPERIMENTAL
Intervention: Placement of metallic stents
Number of subjects: 22
Study: 9477785

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated implants
Number of subjects: 2212

Group type: COMPARATOR
Intervention: Uncoated implants
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Implants in quality 1 and 2 bone
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Implants in quality 3 bone
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Implants in quality 4 bone
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Implants in the posterior maxilla
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Single implants in the anterior maxilla
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Implants in other regions
Number of subjects: 2212
Study: 8463866

Group type: EXPERIMENTAL
Intervention: One dose of albendazole (600 mg, 1x)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Two doses of albendazole (600 mg, 2x)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 3100707

Group type: EXPERIMENTAL
Intervention: Cervical score-based timing of hCG administration
Number of subjects: 42

Group type: COMPARATOR
Intervention: Estradiol and ultrasound-based timing of hCG administration
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cervical score
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cervical score distribution by estradiol levels
Number of subjects: 42
Study: 29529522

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40IU)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 27506866

Group type: COMPARATOR
Intervention: Live tissue training
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: Simulation training
Number of subjects: 742

Group type: COMPARATOR
Intervention: Fluid resuscitation (psychomotor performance)
Number of subjects: 742
Study: 25441567

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral steroid therapy
Number of subjects: 40
Study: 22532110

Group type: EXPERIMENTAL
Intervention: Habit reversal training
Number of subjects: 16
Study: 20422949

Group type: EXPERIMENTAL
Intervention: Valacyclovir hydrochloride (150 mg/capsule, test preparation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Commercially available original capsule (150 mg/capsule, reference preparation)
Number of subjects: 20
Study: 18554394

Group type: EXPERIMENTAL
Intervention: High velocity power training (PT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training (ST)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 45
Study: 15225193

Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg once a day
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg once a day
Number of subjects: 337

Group type: COMPARATOR
Intervention: Mefenamic acid 500 mg three times a day
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg and 15 mg
Number of subjects: 337
Study: 12167389

Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg twice daily
Number of subjects: 0
Study: 9524901

Group type: EXPERIMENTAL
Intervention: 25 mg oral doses of dolasetron mesylate
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: 50 mg oral doses of dolasetron mesylate
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: 100 mg oral doses of dolasetron mesylate
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: 200 mg oral doses of dolasetron mesylate
Number of subjects: 789

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 789
Study: 8591940

Group type: EXPERIMENTAL
Intervention: Itraconazole 5 mg/kg od
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Itraconazole 2.5 mg/kg bd
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Itraconazole 2.5 mg/kg od
Number of subjects: 20
Study: 2655676

Group type: EXPERIMENTAL
Intervention: Japanese BCG vaccine
Number of subjects: 602

Group type: COMPARATOR
Intervention: British BCG vaccine
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 602